首页> 外文期刊>Bone marrow transplantation >Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey
【24h】

Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey

机译:2012年全球造血干细胞移植活动以及对全球血液和骨髓移植网络小组的SWOT分析,包括全球调查

获取原文
获取原文并翻译 | 示例
       

摘要

Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through their regional transplant organizations were analyzed by main indication, donor type and stem cell source for the year 2012. With transplant rates ranging from 0.1 to 1001 per 10 million inhabitants, more HSCTs were registered from unrelated 16 433 donors than related 15 493 donors. Grafts were collected from peripheral blood (66%), bone marrow (24%; mainly non-malignant disorders) and cord blood (10%). Compared with 2006, an increase of 46% total (57% allogeneic and 38% autologous) was observed. Growth was due to an increase in reporting teams (18%) and median transplant activity/team (from 38 to 48 HSCTs/team). An increase of 167% was noted in mismatched/haploidentical family HSCT. A Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis revealed the global perspective of WBMT to be its major strength and identified potential to be the key professional body for patients and authorities. The limited data collection remains its major weakness and threat. In conclusion, global HSCT grows over the years without plateauing (allogeneic>autologous) and at different rates in the four World Health Organization regions. Major increases were observed in allogeneic, haploidentical HSCT and, to a lesser extent, in cord blood transplantation.
机译:由2012年的主要适应症,供体类型和干细胞来源分析了来自77个国家/地区的1566个团队收集的68146例造血干细胞移植(HSCT)(53%自体和47%同种异体)的数据。每1000万居民的移植率在0.1到1001之间,与之相关的15493个捐赠者相比,无关的16433个捐赠者登记的HSCT数量更多。从外周血(66%),骨髓(24%;主要是非恶性疾病)和脐带血(10%)中收集移植物。与2006年相比,总数增加了46%(同种异体的57%和自体的38%)。增长归因于报告团队(18%)和中位数移植活动/团队(从38个HSCT /团队)增加。错配/单亲家庭HSCT增加了167%。优势,劣势,机会,威胁(SWOT)分析显示,WBMT的全球优势是其主要优势,并已确定其潜力是患者和当局的关键专业机构。有限的数据收集仍然是其主要弱点和威胁。总之,多年来,全球HSCT在四个世界卫生组织区域中没有平稳期(同种异体>自体)且以不同的速度增长。在同种异体,单倍体HSCT中观察到大量增加,而在脐血移植中则观察到较小程度的增加。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号